Clinical Trials Logo

Hyperparathyroidism, Secondary clinical trials

View clinical trials related to Hyperparathyroidism, Secondary.

Filter by:

NCT ID: NCT02341417 Completed - Clinical trials for Secondary Hyperparathyroidism, Chronic Kidney Disease

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Start date: June 10, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.

NCT ID: NCT02338934 Not yet recruiting - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients

Start date: January 2015
Phase: Phase 4
Study type: Interventional

This is a single arm, open-labelled study to determine the effectiveness of combination Cinacalcet with Vitamin D analogue in the treatment of severe hyperparathyroidism in patients with ESRF on haemodialysis. Patients will be started on PO Cinacalcet 25mg OD + PO/IV active Vitamin D analogues adjusted by increments/decrements in steps of 1 mcg 3x per week every 1-4 weeks until the corrected calcium level is within 2.4-2.54 mmol/L. After iPTH has reached 2-9x ULN, patient enters maintenance phase. If serum calcium falls below 2.1mmol/L, active Vit D dose will be increased and if it is above 2.54 mmol/L, the dose will be decreased. Percentage reduction of iPTH levels from baseline at 6,12 and 24 months treatment and Percentage of patients achieving iPTH levels within the target range of 2-9x upper limit normal at 6, 12 and 24 months will be determined

NCT ID: NCT02332135 Recruiting - Clinical trials for Secondary Hyperparathyroidism

The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Start date: January 2015
Phase: N/A
Study type: Interventional

Microwave ablation, as a new method to therapy secondary hyperparathyroidism(SHPT), now is developing rapidly. However, it is still unknown whether it is effective to accept microwave ablation for hemodialysis patients with mild-to-moderate SHPT. In this prospective, randomised control and paried clinical trial study, the investigators will observe the efficiency and safety of microwave ablation in hemodialysis patients with mild-to-moderate secondary hyperparathyroidism. The patients in age-matched control group will accept active Vitamin D therapy.

NCT ID: NCT02282813 Completed - Clinical trials for Chronic Kidney Disease

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

Start date: April 2013
Phase: Phase 3
Study type: Interventional

This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.

NCT ID: NCT02274623 Completed - Breast Cancer Clinical Trials

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.

NCT ID: NCT02273570 Recruiting - Clinical trials for Hyperparathyroidism, Secondary

Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

OPTIMAL
Start date: March 2015
Phase: N/A
Study type: Interventional

Clinical study aimed at improving anemia management in End Stage Renal Disease Patient (ESRD) on maintenance Hemodialysis with evidence of Chronic Kidney disease Mineral Bone Disorder (CKD-MBD)

NCT ID: NCT02216656 Completed - Clinical trials for Secondary Hyperparathyroidism

Phase 2 Study of KHK7580

Start date: July 2014
Phase: Phase 2
Study type: Interventional

This randomized, placebo-controlled, double-blind (included open arm of KRN1493 (cinacalcet)), parallel-group, multi-center study is designed to evaluate efficacy and safety in cohorts comprising KHK7580, its placebo and KRN1493 (cinacalcet) orally administered for three weeks for secondary hyperparathyroidism patients receiving hemodialysis.

NCT ID: NCT02143271 Completed - Clinical trials for Secondary Hyperparathyroidism

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.

NCT ID: NCT02138838 Terminated - Clinical trials for Chronic Kidney Disease, Secondary Hyperparathyroidism

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Start date: November 7, 2014
Phase: Phase 3
Study type: Interventional

The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.

NCT ID: NCT02133404 Completed - Clinical trials for Secondary Hyperparathyroidism

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Start date: March 14, 2014
Phase: Phase 2
Study type: Interventional

To examine efficacy and safety after 12-week administration of ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis